Boryung Pharmaceutical

Seoul, South Korea Founded: 1963 • Age: 63 yrs Listed
Finished formulations and APIs are developed for diverse disease areas.

About Boryung Pharmaceutical

Boryung Pharmaceutical is a publicly listed company based in Seoul (South Korea) founded in 1963. Finished formulations and APIs are developed for diverse disease areas. The company has 1,650 employees. Boryung Pharmaceutical has completed 1 acquisition, including ViGenCell. Its chief executive, as recorded, is Tae Choi. Its website boryung.co.kr draws about 106 thousand monthly visits. Boryung Pharmaceutical offers products and services including Pharmaceutical Products and Investor Relations Services. Its focus areas include Traditional Pharmaceuticals and Diversified. Its legal entity is Boryung Co., Ltd.

Company details

Boryung Pharmaceutical was established in 1963 and is headquartered in Seoul, South Korea. Operations focus on the pharmaceutical sector, where active pharmaceutical ingredients (APIs) and finished formulations are produced for multiple disease categories. Development activities span various therapeutic areas, supporting drug manufacturing and distribution primarily within the Asian market. Leadership is provided by CEO Tae Choi, overseeing core research and production processes.

  • Headquarters Seoul, South Korea
  • Employees 1,650
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website boryung.co.kr/en
  • Social Facebook
  • Legal Name Boryung Corporation
Key Metrics
  • Annual Revenue
    $706.27 M (USD)
    0.03
    as on Dec 31, 2025
  • Net Profit
    $44.52 M (USD)
    -7.65
    as on Dec 31, 2025
  • EBITDA
    $75.19 M (USD)
    -4.17
    as on Dec 31, 2025
  • Employee Count
    1,650
  • Investments & Acquisitions

Products & Services of Boryung Pharmaceutical

Boryung Pharmaceutical offers a comprehensive portfolio of products and services, including Pharmaceutical Products and Investor Relations Services.

Pharmaceutical Products
Healthcare Products

Pharmaceutical drugs and related items are offered by the company in the healthcare sector.

Investor Relations Services
Support Services

Information on company history and missions is provided to investors through designated platforms.

People of Boryung Pharmaceutical

1 people are tracked at Boryung Pharmaceutical (1 in leadership); the tracked headcount is 1,650.

NameRoleGroup
Tae Choi
CEOLeadership
Premium access

Complete people profiles for Boryung Pharmaceutical

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Boryung Pharmaceutical

Boryung Pharmaceutical is a publicly listed company on the KRX with ticker symbol 003850 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date24 Oct 1988
  • Listed onKRX: 3850
  • Listed entityBoryung Corporation
  • Exchange sectorHealth technology
  • ISINKR7003850005
  • Share price8,360.00 KRW (-0.12% on the day) · 2026-10-14
  • Market capitalisation707,101,715,012.00 KRW
  • Price to earnings5.8
  • EPS (diluted, trailing year)1,434.59 KRW
  • Dividend yield1.91%
  • Volume (last session)77,032

Financials of Boryung Pharmaceutical

Exchange-reported annual figures
YearRevenueNet incomeEBITDA
20251,020.00B KRW64.30B KRW108.59B KRW
20241,020.00B KRW69.63B KRW113.32B KRW
2023859.63B KRW40.20B KRW112.09B KRW
2022760.48B KRW41.89B KRW93.16B KRW
2021627.28B KRW43.04B KRW73.52B KRW
Premium access

Detailed financial statements for Boryung Pharmaceutical

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Boryung Pharmaceutical

Boryung Pharmaceutical has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include ViGenCell.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
T-cell therapies for tumor treatment are developed by ViGenCell.
vigencell.comSeoul, South Korea2013Aug 2017$1.3M
Premium access

Complete acquisition details for Boryung Pharmaceutical

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Boryung Pharmaceutical

3 dated milestones of Boryung Pharmaceutical across 54 years, from founding to its latest funding, stage changes and deals.

  1. Founded Boryung Pharmaceutical is founded.
  2. IPO Lists on the stock exchange (IPO).
  3. Acquisition Acquires ViGenCell.

Web traffic of Boryung Pharmaceutical

The website of Boryung Pharmaceutical (boryung.co.kr) receives about 106.1K visits a month and ranks #241,973 among all websites worldwide, #174 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    106.1K

    ▲ 17.5% vs previous month

  • Unique visitors
    18.4K

    per month

  • Global rank
    #241,973

    among all websites

  • Category rank
    #174

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with Boryung Pharmaceutical. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
sspharm.co.kr
100%
5.9K#1,210,844View details
ildong.com
100%
79.3K#344,860View details
bukwang.co.kr
100%
142.7K#395,152View details
health.kr
66%
#14,868View details
dailypharm.com
dailypharm.com
62%
#33,384–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
Premium access

All 25 similar websites and full traffic analytics for Boryung Pharmaceutical

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 25 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Boryung Pharmaceutical

Premium access

Complete news archive for Boryung Pharmaceutical

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Boryung Pharmaceutical

Boryung Pharmaceutical was founded in 1963.

Boryung Pharmaceutical is headquartered in Seoul, South Korea.

Tae Choi is the CEO of Boryung Pharmaceutical, as recorded in our data.

Boryung Pharmaceutical has 1,650 employees.

Annual revenue of Boryung Pharmaceutical is $706.27M as on Dec 31, 2025.

Boryung Pharmaceutical was established in 1963 and is headquartered in Seoul, South Korea. Operations focus on the pharmaceutical sector, where active pharmaceutical ingredients (APIs) and finished formulations are produced for multiple disease categories. Development activities span various therapeutic areas, supporting drug manufacturing and distribution primarily within the Asian market. Leadership is provided by CEO Tae Choi, overseeing core research and production processes.

Boryung Pharmaceutical offers Pharmaceutical Products and Investor Relations Services.

Yes, Boryung Pharmaceutical is publicly traded on KRX under the ticker symbol 003850.

Boryung Pharmaceutical has made 1 acquisition, including ViGenCell.

Boryung Pharmaceutical operates through Boryung Co., Ltd.

The website of Boryung Pharmaceutical receives about 106 thousand visits a month and ranks #241,973 among all websites worldwide.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available